Therapeutic Class Overview Benign Prostatic Hyperplasia Treatments.
alpha agonist (alpha2-Adrenergic Agonist) Clonidine/Catapres: Dosage Form . Diseases & Conditions
Members on a standard health plan will have access to over 1,200 maintenance and preventive medications.
All rights reserved.
* The list of available medications is periodically reviewed and may change.
Members on an HSA/QHDHP plan will have access to 800 plus preventive medications. If Rx ‘n Go is a benefit offered by your employer, you’ll get up to a 90-day supply of medications at no cost to you.
Terazosin/Hytrin: Therapeutic Class. hytrin-terazosin-342348
HOW SUPPLIED. Brand of Clonidine.
Start studying Top 300 Med List Quiz 1 generic (Brand) and Therapeutic Class.
Hytrin therapeutic class The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer! "I called customer service and they made it so easy to transfer all six of my refills.
Wonderful staff!”“Rx ‘n Go is simple and easy.
encoded search term (terazosin (Hytrin)) and terazosin (Hytrin) Tadalafil Approved for Benign Prostatic HyperplasiaHow a law designed to encourage production of generic drugs has backfiredFederal and State Laws and Regulations Affecting Managed Care
informational and educational purposes only. Therapeutic Class Overview Benign Prostatic Hyperplasia Agents INTRODUCTION • Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells of the prostate. Terazosin is used to treat high blood pressure (hypertension).. High blood pressure adds to the work load of the heart and arteries. Rx.
Learn vocabulary, terms, and more with flashcards, games, and other study tools. 2010
Catapres, Catapres TTS. Contact the applicable plan Diseases & Conditions
2010 hytrin-terazosin-342348 Drugs Drugs terazosin 2002 451683-overview Diseases & Conditions provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.
Your list will be saved and can be edited at any time.The above information is provided for general * The list of available medications is periodically reviewed and may change.
Diseases & Conditions
May gradually increase to 5 mg PO qHS; up to 20 mg/day beneficial for someMaintenance: 1-5 mg/day or q12hr; may increase to ≤20 mg/day1 mg/day PO; increase dose gradually as necessary; up to maximum of 20 mg/dayAvoid use for hypertension; high risk of orthostatic hypotension (Beers criteria)May cause significant orthostatic hypotension and syncopeLower initial doses than those used for nongeriatric adults, as well as gradual adjustments, are recommended for hypertensionGive first dose and subsequent increases at bedtime to avoid syncopeAdverse effects such as dry mouth and urinary complications can be bothersome in the elderlyCarcinoma of the prostate and BPH cause many of the same symptoms; these two diseases frequently co-exist; patients thought to have BPH should be examined prior to starting therapy to rule out presence of carcinoma of the prostateTherapy can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with first dose or first few days of therapy; a similar effect can be anticipated if therapy is interrupted for several days and then restarted; to decrease likelihood of syncope or excessive hypotension, treatment should always be initiated at a low dose (1 mg) and increased slowly; additional antihypertensive agents should be added with caution; patient should be cautioned to avoid situations, such as driving or hazardous tasks, where injury could result should syncope occur during initiation of therapyIf syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary; there is evidence that orthostatic effect is greater, even in chronic use, shortly after dosing; the risk of the events is greatest during initial seven days of treatment, but continues at all time intervalsWhile syncope is the most severe orthostatic effect, other symptoms of lowered blood pressure, such as dizziness, lightheadedness and palpitations, are more common; patients with occupations in which such events represent potential problems should be treated with particular cautionMay cause CNS depression, which may impair physical or mental abilities; use caution when performing tasks that may require mental alertness, including driving or operating heavy machineryConcomitant administration with PDE-5 inhibitor (eg, sildenafil) can result in additive blood pressure-lowering effects and symptomatic hypotension; initiate PDE-5 inhibitor therapy at lowest doseRisk of priapism (rare); because this condition can lead to permanent impotence if not promptly treated, patients must be advised about seriousness of the conditionLactation: Not known if excreted into breast milk; use cautionA: Generally acceptable.